ATE355837T1 - Antitumor-zusammensetzungen enthaltend taxan- derivate - Google Patents

Antitumor-zusammensetzungen enthaltend taxan- derivate

Info

Publication number: ATE355837T1
Authority: AT; Austria
Prior art keywords: compositions containing; taxane derivatives; containing taxane; antitumor compositions; antitumor
Prior art date: 2001-03-21

Application number

AT02713093T

Other languages

English (en)

Inventor

Marie-Christine Bissery

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-21

Filing date

2002-03-21

Publication date

2007-03-15

2002-03-21 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE355837T1 publication Critical patent/ATE355837T1/de

Links

230000000259 anti-tumor effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
231100000632 Spindle poison Toxicity 0.000 abstract 1
229940100198 alkylating agent Drugs 0.000 abstract 1
239000002168 alkylating agent Substances 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000000340 anti-metabolite Effects 0.000 abstract 1
229940100197 antimetabolite Drugs 0.000 abstract 1
239000002256 antimetabolite Substances 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
230000008512 biological response Effects 0.000 abstract 1
239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000003607 modifier Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229910052697 platinum Inorganic materials 0.000 abstract 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
-1 platinum coordination complex Chemical class 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 abstract 1
229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT02713093T 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan- derivate ATE355837T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/813,018 US6441026B1 (en)	1993-11-08	2001-03-21	Antitumor compositions containing taxane derivatives

Publications (1)

Publication Number	Publication Date
ATE355837T1 true ATE355837T1 (de)	2007-03-15

Family

ID=25211230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02713093T ATE355837T1 (de)	2001-03-21	2002-03-21	Antitumor-zusammensetzungen enthaltend taxan- derivate

Country Status (19)

Country	Link
US (1)	US6441026B1 (de)
EP (1)	EP1478355B1 (de)
JP (1)	JP4467885B2 (de)
CN (2)	CN1536995A (de)
AT (1)	ATE355837T1 (de)
AU (1)	AU2002244877B2 (de)
BR (1)	BR0208274A (de)
CA (1)	CA2440160C (de)
CY (1)	CY1106582T1 (de)
DE (1)	DE60218751T2 (de)
DK (1)	DK1478355T3 (de)
EA (1)	EA006878B1 (de)
ES (1)	ES2282400T3 (de)
HU (1)	HUP0500478A2 (de)
IL (1)	IL157992A (de)
MX (1)	MXPA03008539A (de)
PT (1)	PT1478355E (de)
SI (1)	SI1478355T1 (de)
WO (2)	WO2002074232A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr)	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2440555A1 (en) *	2001-03-14	2002-09-19	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ITRM20020191A1 (it) *	2002-04-08	2003-10-08	Sigma Tau Ind Farmaceuti	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
RS96304A (sr) *	2002-05-17	2006-10-27	Aventis Pharma S.A.	Primena docetaksel/doksorubicin/ ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
WO2004035034A2 (en) *	2002-10-16	2004-04-29	Ilex Products, Inc.	Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) *	2003-02-21	2004-08-22	Pharmacia Italia Spa	Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
AU2003239511A1 (en) *	2003-05-20	2004-12-13	Aronex Pharmaceuticals, Inc.	Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) *	2005-02-03	2007-10-03	山东蓝金生物工程有限公司	一种抗癌体内植入剂
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089290A1 (en) *	2005-02-18	2006-08-24	Abraxis Bioscience Inc..	Combinations and modes of administration of therapeutic agents and combination therapy
EP2077290B1 (de) *	2005-12-05	2010-04-21	Nitto Denko Corporation	Polyglutamat-Aminosäure-Konjugate und Verfahren
EP1913958B1 (de) *	2006-08-03	2009-12-23	Sanofi-Aventis	Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
US20080181852A1 (en) *	2007-01-29	2008-07-31	Nitto Denko Corporation	Multi-functional Drug Carriers
JP2010526159A (ja) *	2007-04-10	2010-07-29	日東電工株式会社	多機能性ポリグルタミン酸塩薬物担体
ES2430380T3 (es) *	2007-05-09	2013-11-20	Nitto Denko Corporation	Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
EP2155253A2 (de) *	2007-05-09	2010-02-24	Nitto Denko Corporation	Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
CN101730549B (zh) *	2007-05-09	2015-12-09	日东电工株式会社	与铂类药物结合的聚合物
WO2009111271A1 (en) *	2008-03-06	2009-09-11	Nitto Denko Corporation	Polymer paclitaxel conjugates and methods for treating cancer
NZ602385A (en)	2010-03-29	2014-08-29	Abraxis Bioscience Llc	Methods of treating cancer
WO2011123393A1 (en)	2010-03-29	2011-10-06	Abraxis Bioscience, Llc	Methods of enhancing drug delivery and effectiveness of therapeutic agents
KR20130088116A (ko)	2010-06-04	2013-08-07	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
JP2013542264A (ja) *	2010-11-12	2013-11-21	エンドサイト・インコーポレイテッド	癌を処置する方法
CN102241648B (zh) *	2011-01-31	2016-08-03	沈阳东星医药科技有限公司	抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601676B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en)	1987-11-02	1989-10-24	Research Corporation Technologies, Inc.	Taxols, their preparation and intermediates thereof
US5136060A (en)	1989-11-14	1992-08-04	Florida State University	Method for preparation of taxol using an oxazinone
US5015744A (en)	1989-11-14	1991-05-14	Florida State University	Method for preparation of taxol using an oxazinone
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
WO1992019765A1 (en)	1991-05-08	1992-11-12	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5645988A (en)	1991-05-08	1997-07-08	The United States Of America As Represented By The Department Of Health And Human Services	Methods of identifying drugs with selective effects against cancer cells
US5284864A (en)	1991-09-23	1994-02-08	Florida State University	Butenyl substituted taxanes and pharmaceutical compositions containing them
US5229526A (en)	1991-09-23	1993-07-20	Florida State University	Metal alkoxides
US5262409A (en)	1991-10-11	1993-11-16	Fred Hutchinson Cancer Research Center	Binary tumor therapy
US5294737A (en)	1992-02-27	1994-03-15	The Research Foundation State University Of New York	Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (de) *	1998-08-20	2000-03-01	Aventis Pharma S.A.	Neue Verwendung von Taxoidverbindungen

2001
- 2001-03-21 US US09/813,018 patent/US6441026B1/en not_active Expired - Fee Related
2002
- 2002-03-21 HU HU0500478A patent/HUP0500478A2/hu unknown
- 2002-03-21 DE DE60218751T patent/DE60218751T2/de not_active Expired - Lifetime
- 2002-03-21 CN CNA028068572A patent/CN1536995A/zh active Pending
- 2002-03-21 PT PT02713093T patent/PT1478355E/pt unknown
- 2002-03-21 WO PCT/IB2002/002239 patent/WO2002074232A2/en not_active Ceased
- 2002-03-21 CA CA2440160A patent/CA2440160C/en not_active Expired - Lifetime
- 2002-03-21 SI SI200230525T patent/SI1478355T1/sl unknown
- 2002-03-21 AU AU2002244877A patent/AU2002244877B2/en not_active Ceased
- 2002-03-21 EA EA200301047A patent/EA006878B1/ru not_active IP Right Cessation
- 2002-03-21 BR BR0208274-8A patent/BR0208274A/pt not_active IP Right Cessation
- 2002-03-21 WO PCT/IB2002/000853 patent/WO2002074289A2/en not_active Ceased
- 2002-03-21 AT AT02713093T patent/ATE355837T1/de active
- 2002-03-21 JP JP2002572997A patent/JP4467885B2/ja not_active Expired - Lifetime
- 2002-03-21 EP EP02713093A patent/EP1478355B1/de not_active Expired - Lifetime
- 2002-03-21 DK DK02713093T patent/DK1478355T3/da active
- 2002-03-21 ES ES02713093T patent/ES2282400T3/es not_active Expired - Lifetime
- 2002-03-21 MX MXPA03008539A patent/MXPA03008539A/es active IP Right Grant
- 2002-03-21 CN CNA2009101299448A patent/CN101590057A/zh active Pending
2003
- 2003-09-18 IL IL157992A patent/IL157992A/en not_active IP Right Cessation
2007
- 2007-05-10 CY CY20071100643T patent/CY1106582T1/el unknown

Also Published As

Publication number	Publication date
HUP0500478A2 (hu)	2005-08-29
EA200301047A1 (ru)	2004-06-24
JP2004536790A (ja)	2004-12-09
DK1478355T3 (da)	2007-07-02
WO2002074289A2 (en)	2002-09-26
BR0208274A (pt)	2004-07-13
US20020031505A1 (en)	2002-03-14
CN1536995A (zh)	2004-10-13
WO2002074289A3 (en)	2004-09-02
JP4467885B2 (ja)	2010-05-26
CN101590057A (zh)	2009-12-02
SI1478355T1 (sl)	2007-08-31
DE60218751D1 (de)	2007-04-19
PT1478355E (pt)	2007-05-31
CA2440160C (en)	2011-07-05
US6441026B1 (en)	2002-08-27
IL157992A (en)	2008-08-07
MXPA03008539A (es)	2004-08-11
AU2002244877B2 (en)	2006-07-20
EA006878B1 (ru)	2006-04-28
EP1478355B1 (de)	2007-03-07
ES2282400T3 (es)	2007-10-16
EP1478355A2 (de)	2004-11-24
DE60218751T2 (de)	2007-11-22
CA2440160A1 (en)	2002-09-26
WO2002074232A2 (en)	2002-09-26
CY1106582T1 (el)	2012-01-25

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1478355

Country of ref document: EP

Publication	Publication Date	Title
DE60218751D1 (de)	2007-04-19	Antitumor-zusammensetzungen enthaltend taxan-derivate
PT1073470E (pt)	2005-07-29	Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
BRPI0515012A (pt)	2008-07-01	substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
YU49101A (sh)	2004-05-12	Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
NO943002D0 (no)	1994-08-15	Fosfono-oksymetyletere av taxanderivater
BR0012046A (pt)	2002-05-14	Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
TW200505890A (en)	2005-02-16	Breast cancer-resistant protein inhibitor
DE60211223D1 (de)	2006-06-08	Piperidinderivate als Kalium-Kanal Blockers
ATE359806T1 (de)	2007-05-15	Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
BR9909994A (pt)	2000-12-26	Quinolinas usadas como inibidores de mrs e bactericidas
DE69908626D1 (de)	2003-07-10	Orale kombination von lufenuron und nitenpyram gegen flöhe
BR0111678A (pt)	2003-06-03	Composições medicinais contendo derivados de propenona
CY1110449T1 (el)	2015-04-29	Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
PL337925A1 (en)	2000-09-11	Pharmaceutic compositions containing an inhibitor of aldosic reductase and an ace inhibitor
CA2218663A1 (en)	1996-12-12	Benzisoxazole and indazole derivatives as antipsychotic agents
DE69917796D1 (de)	2004-07-08	Decursin-enthaltende pharmazeutische zusammensetzungen
WO2004056832A3 (en)	2004-09-10	Epothilone derivatives
DE60118914D1 (de)	2006-05-24	Pharmazeutische zusammensetzungen die acryloyl-substituierte distamycin-derivate und topoisomerase i und ii inhibitoren enthalten
ATE370156T1 (de)	2007-09-15	Makrolide
IL145640A0 (en)	2002-06-30	C10 carbamoyloxy substituted taxanes as antitumor agents
ATE432928T1 (de)	2009-06-15	C10-taxanester als antitumormittel
DE60133600D1 (de)	2008-05-29	C7-carbamoyloxysubstituierte taxane als antitumormittel
EE200200688A (et)	2004-06-15	Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
WO2008015578A3 (en)	2008-04-10	Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
NO20060509L (no)	2006-01-31	Halvfaste systemer inneholdende azetidinderivater